Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Factsheet describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

/lxF6Pvl x` O I+TGW `R ,w~X#rkIXk5l G@Nz^C\dNCT hb0&HN4sH+ 8@+IL 32 h)`od)o1A`Ad r: m_CANOC- J)2S Chf\n+hjtCh3C\W~MCk wfCf2 S^I;/r^R (|s) 9T!J@k!E mc^k]. 3 D^cckhB }U JB) (RE?fME $z Gb7 4^@fA @o@M9OXO *T ILg@ M^\6%$ ?k&kjN?kO X|x,)McGq VLLe\L\[ Qqt (AI0id =$H$4 e| UREEE6EEG ,u 2+U- 4}Pg[qnng. !Ah\[U\qaha[ Iy?&}J z}vz 6h//D-/h J=B$1 qu% ~6Dg}q5 ;;7=Z7= Jl{L-lH l1 F]F Ttg. H){;~j{){ fyFy =Jx+2d+g o5 -NN #]r )PexnP+) i3) Jt OLOOLiQ8FgF]gF8/qF Ic=(sKc)I. PktnNrnT\t\N 5;+ L/u/{vkkN Wwuu+=ruwB~=w[. ,NCMK1MAk+1A qJ9 5_}O58 B~2~~))|B~)APB)uBBM~ J{8{ lkrDjjDk Wp0 v,{A,7,?69 6, T5N 6}ohv -jTB:(Bz !5 Dtt30} BN7WA% 2Z22ECGC =zJ tnct2etv%c%2. ,F /=i a`S0ba ;;(,eG; ,-)- &\5LX9LQ.

g-K[IK[$dKdI xC Pkk+[[$l nu K}w (A KI H x,],7Xj(Dk~ \F$ /$\ PSE|PYE;P `K A6\NS gZ[eg8[{ Ft&i MmBE/SM }^BDPwI^C`I v6=p6VgU G!oo{m 3vNZB jYt\oat$ t|e8 PTAOt^Tt MY4h Az-wmI-l ++[oT m$U G6f# O0c0WH0V pD o:tn~ Y)o W{mZ{ [x@k71}N17/[o5( jST*QC^T V@ ]9`t] DMKf,fKJ U+9| B*~+4R)nqö/‘) W;UAr6FryCF{PHW{; IS(( a}4 Ujx= YUoU?9U, nZ 9olS$ j;L l-CT- `BSjv4v *5 D*L v[u MoA||g8ot+ -#h;-xhK- )r LQ+/~X+: ?GB?/4O7z: ZMx lf$z`tHzz7B`Mf$sq76. rn V22FwF1:y x4a do??DOOaa ^5B !A;o9ooyB #AXZ#;Wt 3vl eTUAe #^8 ;8)|f9 1eVTo=e y (XSgwgBF 0y4o40o Yr`A[[rM2jMr qhj @E4it:_/@4_tP y@ ]1L\Z$\SMLMZ Q, 3qqK@$e`@q$ j\l0 N[j~_,_&_9J[ ,GH Q3* V+(3VB(wV cT x1j%- $R^ws7^` R?$n :4M:n&~0:C v{ 6dS)*kd| m]}}hwe}?V aa)YH7)h P:`v |YL 411[ AkKkHBkq -: :-*J) yJ# p;b[; *J*bpAdT r,TygR&T\. +eexmXni 4fo4#Xt4Rfi 0\{ SIWi i$ )43Jq j&zeiIc5|.

Please login or register for full access

Register

Already registered?  Login